Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

MannKind Corp (NASDAQ:MNKD)

0.99
Delayed Data
As of May 26
 -0.03 / -2.94%
Today’s Change
0.64
Today|||52-Week Range
7.32
-31.72%
Year-to-Date
There Are Crazy Valuations, and Then There Are the Valuations of These 3 Stocks
May 23 / MotleyFool.com - Paid Partner Content
Better Buy: MannKind Corp. vs. Dexcom
May 20 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close1.02
Today’s open1.02
Day’s range0.99 - 1.04
Volume4,318,224
Average volume (3 months)6,285,697
Market cap$487.2M
Dividend yield--
Data as of 3:59pm ET, 05/26/2016

Growth & Valuation

Earnings growth (last year)-78.43%
Earnings growth (this year)+74.18%
Earnings growth (next 5 years)+26.80%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

 Today’s
change
Today’s
% change
ARRYArray Biopharma Inc+0.12+3.57%
SPPISpectrum Pharmaceuti...-0.09-1.20%
OMEROmeros Corp-0.22-1.91%
ENTAEnanta Pharmaceutica...-0.60-2.52%
Data as of 3:59pm ET, 05/26/2016

Financials

Next reporting dateAugust 8, 2016
EPS forecast (this quarter)-$0.05
Annual revenue (last year)$0.00
Annual profit (last year)-$368.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
CEO, CFO, Director, VP &
Head-Investor Relations
Matthew J. Pfeffer
Chief Medical Officer
Raymond W. Urbanski
Corporate headquarters
Valencia, California

Forecasts

Partner Offers

Search for Jobs